Our biosimilar assets include various biosimilar monoclonal antibodies that are developed in our four R&D centers located across Europe and are manufactured in our state-of-the-art facility located in Reykjavik, Iceland.

Our state-of-the-art facility is designed and built to meet highest FDA and EMA GMP requirements globally. Alvotech’s primary focus is on safety, compliance and flexibility.

Alvotech’s international team currently includes over 400 scientists and professionals working at the company’s state-ofthe-art biosimilar facility and headquarters in Reykjavik, Iceland, three other development centers in Hannover and Jülich in Germany as well as Zurich in Switzerland.